Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective observational comparison of XGEVA/ANJIAWEI versus ZOMETA for prevention of skeletal-related events in bone metastases from solid tumors in China
ChiCTR2400079411Phase 4Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jan 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of denosumab and zoledronic acid in bone metastases (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Frequency of administration and duration of treatment of XGEVA/ANJIAWEI and ZOMETA. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
denosumabzoledronic acid
03
Conditions
bone metastases
Beyond the preview
Go deeper on ChiCTR2400079411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079411.